NCT01376505
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult), Senior)
Location of Metastases: 
Additional Notes: The experimental arm of this study has completed, but the extension arm is still recruiting
Exclusions: 
https://ClinicalTrials.gov/show/NCT01376505